HLS Therapeutics Inc. (TSE:HLS - Get Free Report)'s stock price reached a new 52-week low on Friday . The stock traded as low as C$3.00 and last traded at C$3.51, with a volume of 33000 shares trading hands. The stock had previously closed at C$3.84.
Wall Street Analyst Weigh In
Separately, Stifel Nicolaus cut their price objective on shares of HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th.
View Our Latest Research Report on HLS
HLS Therapeutics Price Performance
The company's 50-day moving average price is C$3.48 and its two-hundred day moving average price is C$3.71. The company has a market cap of C$111.58 million, a P/E ratio of -3.31 and a beta of 1.07. The company has a current ratio of 2.02, a quick ratio of 1.01 and a debt-to-equity ratio of 100.44.
HLS Therapeutics (TSE:HLS - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported C($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of C($0.25). HLS Therapeutics had a negative net margin of 40.90% and a negative return on equity of 24.82%. The business had revenue of C$19.87 million during the quarter, compared to the consensus estimate of C$19.25 million. As a group, sell-side analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.
About HLS Therapeutics
(
Get Free Report)
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
